Insider Selling: ICU Medical (NASDAQ:ICUI) COO Sells $1,633,381.97 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian Voigtlander sold 8,929 shares of ICU Medical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

ICU Medical Stock Performance

ICU Medical stock traded down $0.34 during mid-day trading on Tuesday, reaching $182.08. 250,319 shares of the company traded hands, compared to its average volume of 297,071. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $192.85. The company has a market capitalization of $4.55 billion, a price-to-earnings ratio of 154.31, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The firm’s fifty day moving average is $152.66 and its two-hundred day moving average is $141.12.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same quarter last year, the company posted $2.10 earnings per share. The business’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, equities research analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the company. Wall Street Zen raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Piper Sandler raised their price objective on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday. KeyCorp lifted their target price on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Finally, Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $192.80.

Institutional Investors Weigh In On ICU Medical

Several hedge funds have recently added to or reduced their stakes in ICUI. Allworth Financial LP acquired a new stake in ICU Medical during the 2nd quarter worth about $26,000. Hilton Head Capital Partners LLC acquired a new position in shares of ICU Medical in the 4th quarter valued at about $32,000. Covestor Ltd boosted its stake in shares of ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 126 shares during the last quarter. Strs Ohio boosted its stake in shares of ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after buying an additional 300 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its holdings in ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 146 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.